PPARγ as a therapeutic target in cystic fibrosis

Cystic fibrosis (CF) is characterized by a proinflammatory pulmonary condition that may result from increased infections and altered intracellular metabolism in CFTR-deficient cells. The lipid-activated transcription factor peroxisome proliferator-activated receptor-γ (PPARγ) has well-established roles in immune cell function and inflammatory modulation and has been demonstrated to play an important role in the heightened inflammatory response in CF cells. Here, we summarize current literature describing PPARγ-dependent alterations of CF cells and discuss the potential of PPARγ ligands for treating CF.

Authors: 
J.F. Dekkers, C.K. van der Ent, E. Kalkhoven, J.M. Beekman
Authors from the NMC: 
DOI: 
10.1016/j.molmed.2012.03.004
Pages: 
2012; 18(5): 283-91
Published in: 
Trends in Molecular Medicine
Date of publication: 
May, 2012
Status of the publication: 
Published/accepted